FDA Expands Approval of Omalizumab for Food Allergies After Promising Study

The drug omalizumab, known as Xolair, significantly reduces severe allergic reactions in children, offering a new layer of protection against food allergens.

A new study reveals that the drug omalizumab, also known as Xolair, significantly reduces the risk of severe allergic reactions in children with food allergies to substances like peanuts, cashews, milk, and eggs.
The FDA has expanded approval of omalizumab for use in individuals with food allergies, based on the promising results of the study.
Omalizumab works by targeting and neutralizing IgE antibodies responsible for allergic reactions, offering protection against accidental exposure to allergens.
The drug is administered via injection every two to four weeks and has been shown to be safe for use in children as young as one year old.
Further research is needed to understand the long-term efficacy of omalizumab and its potential to improve other allergic conditions.